🔹Freenome Inc., a specialist in multi-omics liquid biopsy, has raised $254 million in financing led by Roche AG.
🔹The funding will be used to support the testing of Freenome’s early cancer detection platform.
🔹The company aims to recruit 6,200 patients for the Vallania Study to identify cancer-specific patterns in the blood using AI.
🔹The funding round saw participation from several other investors, including a16z Life Sciences Growth Fund and Quest Diagnostics.
🔹The funding will be used to support the testing of Freenome’s early cancer detection platform.
🔹The company aims to recruit 6,200 patients for the Vallania Study to identify cancer-specific patterns in the blood using AI.
🔹The funding round saw participation from several other investors, including a16z Life Sciences Growth Fund and Quest Diagnostics.
📢 Roche Leads $254M Funding for Cancer Detection Breakthrough
Introduction:
Swiss pharmaceutical company Roche AG has led a financing round of $257 million for Freenome Inc, a multi-omics liquid biopsy specialist. The funding will be used to support Freenome’s AI-guided cancer detection platform, which aims to detect cancer in its early stages.
Main points:
- The financing round was led by Roche and included participation from a variety of other investors.
- Freenome will use the funding to test its early cancer detection platform in the Vallania Study, which aims to recruit 6,200 patients.
- The study will use Freenome’s AI algorithm to identify cancer-specific multi-omics patterns in the blood.
- The goal is to develop a non-invasive method of cancer detection that can detect the disease in its earliest, most treatable stages.
- Freenome is also developing tests to screen for other types of cancer and is working with biopharma and diagnostic partners to evaluate its platform.
Conclusion:
Roche’s investment in Freenome’s cancer detection platform highlights the potential of liquid biopsy-based tests for early cancer detection. By using AI algorithms and multi-omics analysis, Freenome aims to develop a non-invasive screening tool that can detect cancer in its early stages, when it is most treatable. This could have significant implications for cancer diagnosis and treatment, potentially leading to improved outcomes for patients.
